Left ventricular hypertrophy by electrocardiogram as a predictor of success in home blood pressure control

HOMED-BP study

Ayumi Tanabe, Kei Asayama, Tomohiro Hanazawa, Daisuke Watabe, Kyoko Nomura, Tomonori Okamura, Takayoshi Ohkubo, Yutaka Imai

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Few studies have focused on the effect of organ damage on achievement of long-term home blood pressure (BP) control. Based on the nationwide home BP-based trial data, we aimed to investigate the factors associated with home BP control, in particular, left ventricular hypertrophy (LVH) using the electrocardiogram in patients who started antihypertensive drug treatment. According to the trial protocol, we defined BP as controlled when systolic home BP reached specified targets (125-134 mm Hg in usual control (UC), n=1261; <125 mm Hg in tight control (TC), n=1288). At baseline, before drug treatment started, the mean Sokolow-Lyon voltage was 2.57±0.87 mV, and the mean Cornell product was 1573±705 mm·ms. The numbers of patients who achieved the target BP level in the UC and TC groups were 892 (70.7%) and 576 (44.7%), respectively. In both the UC and TC groups, systolic home BP at baseline was significantly lower in patients who achieved target levels than in those who did not achieve target levels (P<0.0001). Sokolow-Lyon voltage was significantly lower in patients who achieved target levels than in those who did not (P≤0.0055). The Cornell product levels in each group were similar (P≥0.12), although significantly different between patients who did or did not achieve the target level when the UC and TC groups were combined for analysis (P=0.031). Sokolow-Lyon voltage was significantly associated with achievement of home BP control in the multivariable-adjusted model (odds ratio, 1.13; 95% confidence intervals, 1.02-1.26; P=0.015), but Cornell product was not (P=0.13). These results indicate the difficulty of sufficient antihypertensive treatment when untreated patients had target organ damage, that is, LVH diagnosed by Sokolow-Lyon voltage.

Original languageEnglish
Pages (from-to)504-510
Number of pages7
JournalHypertension Research
Volume40
Issue number5
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Left Ventricular Hypertrophy
Electrocardiography
Blood Pressure
Control Groups
Antihypertensive Agents
Group Homes
Clinical Protocols
Therapeutics
Odds Ratio
Confidence Intervals
Pharmaceutical Preparations

Keywords

  • antihypertensive drug treatment
  • Cornell product
  • home blood pressure
  • left ventricular hypertrophy
  • Sokolow-Lyon voltage

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Left ventricular hypertrophy by electrocardiogram as a predictor of success in home blood pressure control : HOMED-BP study. / Tanabe, Ayumi; Asayama, Kei; Hanazawa, Tomohiro; Watabe, Daisuke; Nomura, Kyoko; Okamura, Tomonori; Ohkubo, Takayoshi; Imai, Yutaka.

In: Hypertension Research, Vol. 40, No. 5, 01.05.2017, p. 504-510.

Research output: Contribution to journalArticle

Tanabe, Ayumi ; Asayama, Kei ; Hanazawa, Tomohiro ; Watabe, Daisuke ; Nomura, Kyoko ; Okamura, Tomonori ; Ohkubo, Takayoshi ; Imai, Yutaka. / Left ventricular hypertrophy by electrocardiogram as a predictor of success in home blood pressure control : HOMED-BP study. In: Hypertension Research. 2017 ; Vol. 40, No. 5. pp. 504-510.
@article{2eeaf1591bf6423a837b7ce2be7b2986,
title = "Left ventricular hypertrophy by electrocardiogram as a predictor of success in home blood pressure control: HOMED-BP study",
abstract = "Few studies have focused on the effect of organ damage on achievement of long-term home blood pressure (BP) control. Based on the nationwide home BP-based trial data, we aimed to investigate the factors associated with home BP control, in particular, left ventricular hypertrophy (LVH) using the electrocardiogram in patients who started antihypertensive drug treatment. According to the trial protocol, we defined BP as controlled when systolic home BP reached specified targets (125-134 mm Hg in usual control (UC), n=1261; <125 mm Hg in tight control (TC), n=1288). At baseline, before drug treatment started, the mean Sokolow-Lyon voltage was 2.57±0.87 mV, and the mean Cornell product was 1573±705 mm·ms. The numbers of patients who achieved the target BP level in the UC and TC groups were 892 (70.7{\%}) and 576 (44.7{\%}), respectively. In both the UC and TC groups, systolic home BP at baseline was significantly lower in patients who achieved target levels than in those who did not achieve target levels (P<0.0001). Sokolow-Lyon voltage was significantly lower in patients who achieved target levels than in those who did not (P≤0.0055). The Cornell product levels in each group were similar (P≥0.12), although significantly different between patients who did or did not achieve the target level when the UC and TC groups were combined for analysis (P=0.031). Sokolow-Lyon voltage was significantly associated with achievement of home BP control in the multivariable-adjusted model (odds ratio, 1.13; 95{\%} confidence intervals, 1.02-1.26; P=0.015), but Cornell product was not (P=0.13). These results indicate the difficulty of sufficient antihypertensive treatment when untreated patients had target organ damage, that is, LVH diagnosed by Sokolow-Lyon voltage.",
keywords = "antihypertensive drug treatment, Cornell product, home blood pressure, left ventricular hypertrophy, Sokolow-Lyon voltage",
author = "Ayumi Tanabe and Kei Asayama and Tomohiro Hanazawa and Daisuke Watabe and Kyoko Nomura and Tomonori Okamura and Takayoshi Ohkubo and Yutaka Imai",
year = "2017",
month = "5",
day = "1",
doi = "10.1038/hr.2016.176",
language = "English",
volume = "40",
pages = "504--510",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Left ventricular hypertrophy by electrocardiogram as a predictor of success in home blood pressure control

T2 - HOMED-BP study

AU - Tanabe, Ayumi

AU - Asayama, Kei

AU - Hanazawa, Tomohiro

AU - Watabe, Daisuke

AU - Nomura, Kyoko

AU - Okamura, Tomonori

AU - Ohkubo, Takayoshi

AU - Imai, Yutaka

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Few studies have focused on the effect of organ damage on achievement of long-term home blood pressure (BP) control. Based on the nationwide home BP-based trial data, we aimed to investigate the factors associated with home BP control, in particular, left ventricular hypertrophy (LVH) using the electrocardiogram in patients who started antihypertensive drug treatment. According to the trial protocol, we defined BP as controlled when systolic home BP reached specified targets (125-134 mm Hg in usual control (UC), n=1261; <125 mm Hg in tight control (TC), n=1288). At baseline, before drug treatment started, the mean Sokolow-Lyon voltage was 2.57±0.87 mV, and the mean Cornell product was 1573±705 mm·ms. The numbers of patients who achieved the target BP level in the UC and TC groups were 892 (70.7%) and 576 (44.7%), respectively. In both the UC and TC groups, systolic home BP at baseline was significantly lower in patients who achieved target levels than in those who did not achieve target levels (P<0.0001). Sokolow-Lyon voltage was significantly lower in patients who achieved target levels than in those who did not (P≤0.0055). The Cornell product levels in each group were similar (P≥0.12), although significantly different between patients who did or did not achieve the target level when the UC and TC groups were combined for analysis (P=0.031). Sokolow-Lyon voltage was significantly associated with achievement of home BP control in the multivariable-adjusted model (odds ratio, 1.13; 95% confidence intervals, 1.02-1.26; P=0.015), but Cornell product was not (P=0.13). These results indicate the difficulty of sufficient antihypertensive treatment when untreated patients had target organ damage, that is, LVH diagnosed by Sokolow-Lyon voltage.

AB - Few studies have focused on the effect of organ damage on achievement of long-term home blood pressure (BP) control. Based on the nationwide home BP-based trial data, we aimed to investigate the factors associated with home BP control, in particular, left ventricular hypertrophy (LVH) using the electrocardiogram in patients who started antihypertensive drug treatment. According to the trial protocol, we defined BP as controlled when systolic home BP reached specified targets (125-134 mm Hg in usual control (UC), n=1261; <125 mm Hg in tight control (TC), n=1288). At baseline, before drug treatment started, the mean Sokolow-Lyon voltage was 2.57±0.87 mV, and the mean Cornell product was 1573±705 mm·ms. The numbers of patients who achieved the target BP level in the UC and TC groups were 892 (70.7%) and 576 (44.7%), respectively. In both the UC and TC groups, systolic home BP at baseline was significantly lower in patients who achieved target levels than in those who did not achieve target levels (P<0.0001). Sokolow-Lyon voltage was significantly lower in patients who achieved target levels than in those who did not (P≤0.0055). The Cornell product levels in each group were similar (P≥0.12), although significantly different between patients who did or did not achieve the target level when the UC and TC groups were combined for analysis (P=0.031). Sokolow-Lyon voltage was significantly associated with achievement of home BP control in the multivariable-adjusted model (odds ratio, 1.13; 95% confidence intervals, 1.02-1.26; P=0.015), but Cornell product was not (P=0.13). These results indicate the difficulty of sufficient antihypertensive treatment when untreated patients had target organ damage, that is, LVH diagnosed by Sokolow-Lyon voltage.

KW - antihypertensive drug treatment

KW - Cornell product

KW - home blood pressure

KW - left ventricular hypertrophy

KW - Sokolow-Lyon voltage

UR - http://www.scopus.com/inward/record.url?scp=85019019793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019019793&partnerID=8YFLogxK

U2 - 10.1038/hr.2016.176

DO - 10.1038/hr.2016.176

M3 - Article

VL - 40

SP - 504

EP - 510

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 5

ER -